SCHEMBL798331

SCHEMBL798331

O=C1c2ccccc2CCN1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.48
CYP2A6 P11509 1/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
CES1 P23141 1/20 0.48
BCAT2 O15382 2/20 0.46
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
RNASEH1 O60930 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HTR2C P28335 4/20 0.41
HTR2B P41595 4/20 0.41
HTR2A P28223 3/20 0.41
PDPK1 O15530 1/20 0.41
PARP1 P09874 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP11 Q9NR21 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29965051 1.00 KMT2A (0.48) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL3697489 0.79 KMT2A (0.63) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL30617863 0.79 KMT2A (0.63) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL28818090 0.76 KMT2A (0.48) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL677630 0.76 GRM5 (0.58) KMT2AMAOAMAOBCES1BCAT2
SCHEMBL25027414 0.76 KMT2A (0.48) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL11407629 0.76 BCAT2 (0.50) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL31019547 0.76 BCAT2 (0.50) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL10672107 0.76 CES1 (0.54) KMT2ACYP2A6MAOAMAOBCES1
SCHEMBL793778 0.76 KMT2A (0.44) KMT2ACYP2A6MAOAMAOBCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 KMT2A 660/4885CYP2A6 112/4885MAOA 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.